287 related articles for article (PubMed ID: 16416732)
1. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.
Hassan R; Laszik ZG; Lerner M; Raffeld M; Postier R; Brackett D
Am J Clin Pathol; 2005 Dec; 124(6):838-45. PubMed ID: 16416732
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
Argani P; Iacobuzio-Donahue C; Ryu B; Rosty C; Goggins M; Wilentz RE; Murugesan SR; Leach SD; Jaffee E; Yeo CJ; Cameron JL; Kern SE; Hruban RH
Clin Cancer Res; 2001 Dec; 7(12):3862-8. PubMed ID: 11751476
[TBL] [Abstract][Full Text] [Related]
3. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
4. Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma.
Baruch AC; Wang H; Staerkel GA; Evans DB; Hwang RF; Krishnamurthy S
Diagn Cytopathol; 2007 Mar; 35(3):143-7. PubMed ID: 17304533
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis.
Ibrahim DA; Abouhashem NS
Pathol Res Pract; 2016 Apr; 212(4):288-93. PubMed ID: 26874572
[TBL] [Abstract][Full Text] [Related]
6. Immunostaining as an adjunct to cytology for diagnosis of pancreatic adenocarcinoma.
Agarwal B; Ludwig OJ; Collins BT; Cortese C
Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1425-31. PubMed ID: 19081530
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold.
Goldstein NS; Bassi D
Am J Clin Pathol; 2001 May; 115(5):695-702. PubMed ID: 11345833
[TBL] [Abstract][Full Text] [Related]
8. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
Inami K; Kajino K; Abe M; Hagiwara Y; Maeda M; Suyama M; Watanabe S; Hino O
Oncol Rep; 2008 Dec; 20(6):1375-80. PubMed ID: 19020717
[TBL] [Abstract][Full Text] [Related]
9. [Preferential expression of cartilage oligomeric matrix protein in degenerating acinar cells in chronic pancreatitis and in chronic pancreatitis-like lesions].
Liao Q; Zhao YP; Kleeff J; Xiao Y; Zimmermann A; Buchler MW; Friess H
Zhonghua Wai Ke Za Zhi; 2003 May; 41(5):328-31. PubMed ID: 12892583
[TBL] [Abstract][Full Text] [Related]
10. Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas.
Evans JD; Cornford PA; Dodson A; Greenhalf W; Foster CS; Neoptolemos JP
Pancreatology; 2001; 1(3):254-62. PubMed ID: 12120204
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma.
Einama T; Kamachi H; Nishihara H; Homma S; Kanno H; Takahashi K; Sasaki A; Tahara M; Okada K; Muraoka S; Kamiyama T; Matsuno Y; Ozaki M; Todo S
Pancreas; 2011 Nov; 40(8):1276-82. PubMed ID: 21775916
[TBL] [Abstract][Full Text] [Related]
12. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma.
Masaki Y; Oka M; Ogura Y; Ueno T; Nishihara K; Tangoku A; Takahashi M; Yamamoto M; Irimura T
Hepatogastroenterology; 1999; 46(28):2240-5. PubMed ID: 10521973
[TBL] [Abstract][Full Text] [Related]
13. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
Cao D; Ji H; Ronnett BM
Int J Gynecol Pathol; 2005 Jan; 24(1):67-72. PubMed ID: 15626919
[TBL] [Abstract][Full Text] [Related]
14. Application of mesothelin immunostaining in tumor diagnosis.
Ordóñez NG
Am J Surg Pathol; 2003 Nov; 27(11):1418-28. PubMed ID: 14576474
[TBL] [Abstract][Full Text] [Related]
15. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
Liu H; Shi J; Anandan V; Wang HL; Diehl D; Blansfield J; Gerhard G; Lin F
Arch Pathol Lab Med; 2012 Jun; 136(6):601-9. PubMed ID: 22646265
[TBL] [Abstract][Full Text] [Related]
16. Expression of intermediate filaments in normal and neoplastic exocrine pancreas.
Santini D; Ceccarelli C; Martinelli GN; Pasquinelli G; Leone O; Marrano D; Mancini AM
Zentralbl Pathol; 1994 Aug; 140(3):247-58. PubMed ID: 7524653
[TBL] [Abstract][Full Text] [Related]
17. Distribution of type IV collagen in pancreatic adenocarcinoma and chronic pancreatitis.
Lee CS; Montebello J; Georgiou T; Rode J
Int J Exp Pathol; 1994 Apr; 75(2):79-83. PubMed ID: 8199008
[TBL] [Abstract][Full Text] [Related]
18. Multiparameter digital image analysis of biliary, ampullary, and pancreatic adenocarcinomas.
Yeaton P; Kiss R; DePrez C; Salmon I; Pasteels JL; Jones RS; Frierson HF
Mod Pathol; 1995 Oct; 8(8):843-7. PubMed ID: 8552573
[TBL] [Abstract][Full Text] [Related]
19. Expression of heat shock proteins in chronic pancreatitis: protective or pathogenic roles?
Slater S; Jalleh R; Gilbertson J; Lampert I; Williamson R; Foster CS
Lab Invest; 1997 Apr; 76(4):533-45. PubMed ID: 9111515
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma.
Crnogorac-Jurcevic T; Gangeswaran R; Bhakta V; Capurso G; Lattimore S; Akada M; Sunamura M; Prime W; Campbell F; Brentnall TA; Costello E; Neoptolemos J; Lemoine NR
Gastroenterology; 2005 Nov; 129(5):1454-63. PubMed ID: 16285947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
